Beyond DEA/DOJ: The Federal Agencies That Will Decide Cannabis's Fate

Photo by K via Pexels.

Everyone in the industry spent December popping metaphorical champagne when word got out that marijuana was finally moving off Schedule I. Executive Order 14370 in December 2025, followed by Acting Attorney General Todd Blanche's formal order on April 23, 2026, made it official: cannabis is no longer classified alongside heroin in the eyes of federal drug law, at least for part of the market. That fight, the one that's dominated cannabis headlines for the better part of a decade, is basically over.

Here's the part that got buried under the celebration: the reschedule only covers two narrow lanes. FDA-approved marijuana drug products, and marijuana dispensed under a state-licensed medical program, are now Schedule III. Everything else -- the adult-use flower, edibles, and vapes sold in Colorado, California, Illinois, and every other recreational market -- stays exactly where it's always been, Schedule I, right next to LSD and heroin. And recreational sales are the overwhelming majority of legal cannabis revenue in this country.

So while the DEA and DOJ get the headlines, the agencies that actually determine whether this industry turns a profit or stays a cash-strapped, half-legal curiosity are quieter ones: Treasury and the IRS, the ATF, and FinCEN. Rescheduling was the flashy announcement. These are the agencies writing the fine print that decides who actually gets paid.

The Rescheduling Fine Print Everyone Skipped Past

Photo by Matthew Jackson via Pexels.

Read past the press releases and the actual text of Blanche's April 23 order is narrower than most coverage suggested. It moves marijuana to Schedule III in exactly two circumstances: when it's part of an FDA-approved drug product, think Epidiolex-style pharmaceuticals, or when it's dispensed to a patient under a state medical marijuana license. That's it. Nothing in the order touches adult-use cannabis sold at a recreational dispensary, even in states where that program has operated legally for a decade.

That distinction matters enormously in mixed markets. A dispensary in a state like Michigan or New Jersey that serves both medical cardholders and recreational customers is now operating two different federal realities under one roof, one register, and often one product line. The medical sale might get treated as Schedule III activity; the recreational sale next to it stays Schedule I. Untangling that at the accounting and compliance level is not a small lift, and guidance from federal agencies on how to actually separate those revenue streams has been thin.

There's a second track that could theoretically widen the reschedule, but don't bet on it moving fast. A DEA administrative hearing on broader rescheduling opened June 29, 2026, with a mandated conclusion by July 15, 2026. Even if that process pushes marijuana further down the schedule, or expands who qualifies, there's no guarantee it resolves the recreational carve-out. DEA hearings of this type tend to produce narrow, technical outcomes rather than sweeping policy shifts, and the agency has shown no appetite for handing adult-use operators the same treatment as state-licensed medical programs. For now, operators need to plan around a bifurcated system, not a fully rescheduled one.

Treasury and the IRS: Where the Real Money Fight Is

Repealing Section 280E could save the U.S. cannabis industry an estimated $1.6 billion, dwarfing the $96.5 million tax liability already disclosed by a single company, Curaleaf.

Treasury and the IRS didn't waste time weighing in once Blanche's order landed. On the same day, April 23, 2026, both agencies signaled that rescheduling should bring significant, positive tax consequences, but only for the medical marijuana side of the business. The expected transition rule would apply retroactively across the entire 2026 taxable year, meaning qualifying medical operators could claim a full year of ordinary business deductions instead of being stuck under the punishing restrictions of Section 280E, the tax code provision that has long blocked cannabis companies from writing off standard business expenses.

Recreational cannabis gets none of that relief. Since adult-use marijuana remains Schedule I, the operators generating the bulk of legal cannabis revenue in states like California and Colorado are still boxed into 280E, still unable to deduct rent, payroll, or marketing the way any other business can.

The IRS is also actively fighting attempts to apply relief retroactively or expansively. On May 18, 2026, the agency sued TerrAscend, seeking repayment of tax refunds it says were paid out in error. In New Mexico's Top Organics v. Commissioner case, the IRS argued in a March 6, 2026 filing that the operator's interpretation of the tax code would produce what it bluntly called an absurd result. This is not an agency conceding ground quietly.

The dollar figures explain why the IRS is digging in. Industry analysts have floated roughly $1.6 billion in potential savings for major multi-state operators if 280E stopped applying altogether. Curaleaf alone disclosed $96.5 million in uncertain tax liabilities tied to 280E as of May 5, 2026. That's the size of the fight Treasury and the IRS are managing, one balance sheet at a time.

ATF Is Quietly Rewriting the Gun-Buyer Question

Photo by Dimitri Karastelev via Unsplash.

Buried away from the tax and scheduling news, the ATF has been quietly rewriting one of the most consequential forms in federal gun law. Form 4473, the questionnaire every licensed firearms dealer uses to screen buyers, has long included a question asking whether the buyer uses marijuana or any other federally illegal drug, regardless of state law. Answer yes, and federal law treats you as a prohibited person for firearm purchases, no matter how legal your cannabis use is under your state's medical or recreational program.

The ATF posted a draft revision of Form 4473 that shortens the document from seven pages down to four, with public comments accepted through July 7, 2026, ahead of final publication. Buried in that revision is a narrower marijuana-use question, one that focuses specifically on recreational use rather than a blanket catch-all. The intent appears to be letting state-legal medical patients answer honestly without automatically triggering a denial at the counter.

This sounds like a technical form-drafting exercise, but it touches millions of people. States with established medical marijuana programs have registered patients numbering in the millions collectively, and a meaningful share of them are also gun owners or would-be gun buyers in states with strong firearms cultures. Right now, those two identities are legally incompatible at the federal level, and the mismatch has produced years of quiet workarounds, denials, and in some cases criminal exposure for patients who simply didn't disclose. If ATF's revised form actually threads that needle, it would be one of the more practically significant changes to come out of this entire policy shift, even though it will never get the attention rescheduling got.

FinCEN and Banking: Schedule III Doesn't Solve the Vault Problem

Photo by RDNE Stock project via Pexels.

None of this touches the problem that has haunted cannabis banking since state legalization began: there is still no dedicated federal statute authorizing banks to serve cannabis businesses. The operative framework remains FinCEN guidance FIN-2014-G001, a document written more than a decade ago specifically for a Schedule I substance. Now that a slice of the market sits on Schedule III, that guidance doesn't cleanly map onto the current landscape, and FinCEN hasn't issued an update to clarify how banks should treat medical versus recreational cannabis revenue differently, if at all.

That leaves banks and credit unions in a familiar bind. Compliance officers still have to decide which cannabis-related deposits count as low-risk and which count as high-risk, and the rescheduling split gives them a new wrinkle without a new rulebook to interpret it. Most institutions, understandably, err toward caution, which means plenty of cannabis businesses still get turned away or charged steep account-servicing fees even in states where they're fully licensed.

Congress has tried to fix this before. The SAFE Banking Act was reintroduced with bipartisan sponsorship in June 2026, marking yet another attempt at a bill that has already passed the House seven separate times without ever clearing the Senate. There's no reason to assume this attempt breaks that streak just because rescheduling happened.

Until FinCEN updates its guidance or Congress actually passes something, the day-to-day reality for most cannabis businesses doesn't change much: heavy cash handling, limited access to standard banking services, and constant improvisation around a financial system that still isn't built for them.

Rescheduling was always going to be the easy win politically. It's a single order, a clean headline, a milestone advocates could point to after years of pushing. The harder, slower work now sits with Treasury, the IRS, the ATF, and FinCEN, and their decisions over the next year will determine whether this industry actually becomes profitable and bankable or just adds another layer of federal bureaucracy on top of the one it already had.

Multi-state operators hoping for quick 280E relief should keep a close eye on the TerrAscend lawsuit and the Top Organics case out of New Mexico. The IRS has made clear through its March 2026 filing and its pursuit of TerrAscend that it isn't handing back tax dollars without a fight, and the outcome of those cases will shape how aggressively other operators can pursue retroactive claims.

If you're trying to actually track where this industry is headed, DEA press releases aren't where the story is anymore. Treasury guidance, FinCEN advisories, and the ATF's Form 4473 rulemaking docket are where the decisions that matter are actually getting made, quietly, without the fanfare that greeted rescheduling itself.

And as always, the details vary sharply by state and shift on a timeline that outpaces most news coverage. Anyone running a cannabis business, or just trying to understand their own rights as a consumer or patient, should confirm current law in their own jurisdiction rather than assume that one executive order rewrote the whole system overnight. It didn't.